Diabetes

A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of the fixed dose combination of Empagliflozin 10 mg/Linagliptin 5 mg compared with Empagliflozin 10 mg alone and the efficacy and safety of Empagliflozin 25 mg/Linagliptin 5 mg compared with Empagliflozin 25 mg alone each administered orally once daily over 24 weeks in patients with type 2 diabetes mellitus who have insufficient glycaemic control after 16 weeks of treatment with Empagliflozin 10 mg or Empagliflozin 25 mg once daily and maximum tolerated dose of metformin IR.

Register Today!

Let others know about this Trial!

Trial Information

StatusCompleted
Trial Duration24 weeks
Number of Visits10
Lead CRCJason Collin

For additional information
on this trial contact:

Phone705-566-0005